Applied Microbiology and Biotechnology

, Volume 73, Issue 4, pp 815–826 | Cite as

Identification and characterization of IS1 transposition in plasmid amplification mutants of E. coli clones producing DNA vaccines

  • Kristala L. Jones Prather
  • M. Celina Edmonds
  • Jerrell W. Herod
Biotechnologically Relevant Enzymes and Proteins


Merck Research Laboratories has developed a highly productive Escherichia coli fermentation process to produce plasmid DNA for use as vaccines. The process consists of a fed-batch fermentation in a chemically defined medium. Initiation of the feed stream precedes a growth-limited phase in which plasmid DNA is amplified. The fermentation is only maximally productive for a small fraction of E. coli transformants designated as high-producers, while the predominant low-producer population does not amplify plasmid DNA. In experiments undertaken to probe this phenomenon, transposition of the 768-bp E. coli insertion sequence IS1 into an HIV DNA vaccine vector was observed in several low-producer clones. IS1 was found to insert in or near the neomycin resistance gene in nearly a dozen unique sites from within a single population of plasmid molecules. The fraction of IS1-containing plasmids within several clones was determined by quantitative polymerase chain reaction and was found to increase with increasing cultivation time in the chemically defined medium. Because transposition into an antibiotic-resistance gene is unlikely to affect plasmid amplification, the genomes of high- and low-producers of three different HIV DNA vaccine vectors were subsequently profiled by restriction fragment length polymorphism analysis. In all three cases, IS1 insertional mutations were found in the genomes of the predominant low-producers, while the genomes of the high-producers were indistinguishable from untransformed cells. The insertions reside on similarly sized fragments for two of the low-producer clones, and the fragment size is smaller for the third clone. The third clone also produces much less plasmid DNA than a typical low-producer. The results suggest the presence of an IS1 insertional mutation that affects plasmid replication and amplification, possibly in a position-dependent manner.


DNA vaccine IS1 transposition Q-PCR RFLP 


  1. Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM, Wagner W, Bilska M, Craiu A, Zheng XX, Krivulka GR, Beaudry K, Lifton MA, Nickerson CE, Trigona WL, Punt K, Freed DC, Guan L, Dubey S, Casimiro D, Simon A, Davies ME, Chastain M, Strom TB, Gelman RS, Montefiori DC, Lewis MG, Emini EA, Shiver JW, Letvin NL (2000) Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290:486–492CrossRefGoogle Scholar
  2. Boyd AC, Popp F, Michaelis U, Davidson H, Davidson-Smith H, Doherty A, McLachlan G, Porteous DJ, Seeber S (1999) Insertion of natural intron 6a–6b into a human cDNA-derived gene therapy vector for cystic fibrosis improves plasmid stability and permits facile RNA/DNA discrimination. J Gene Med 1:312–321CrossRefGoogle Scholar
  3. Carnes AE (2005) Fermentation design for the manufacture of therapeutic plasmid DNA. BioProcess Int 3:36–44Google Scholar
  4. Casimiro DR, Tang A, Perry HC, Long RS, Chen M, Heidecker GJ, Davies M-E, Freed DC, Persaud NV, Dubey S, Smith JG, Havlir D, Richman D, Chastain MA, Simon AJ, Fu T-M, Emini EA, Shiver JW (2002) Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized Human Immunodeficiency Virus Type 1 pol gene. J Virol 76:185–194CrossRefGoogle Scholar
  5. Caulfield MJ, Wang S, Smith JG, Tobery TW, LIu X, Davies M-E, Casimiro DR, Fu T-M, Simon A, Evans RK, Emini EA, Shiver JW (2002) Sustained peptide-specific gamma interferon T-cell response in Rhesus macaques immunized with human immunodeficiency virus gag DNA vaccines. J Virol 76:10038–10043CrossRefGoogle Scholar
  6. Chartrain M, Bentley LK, Krulewicz BA, Listner KM, Sun W-J, Lee CB (2005) Process for large scale production of plasmid DNA by E. coli fermentation. WO 2005/078115. Merck, USAGoogle Scholar
  7. Chen W (1999) Automated high-yield fermentation of plasmid DNA in Escherichia coli. US Patent 5,995,323 (American Home Products)Google Scholar
  8. Chen J-H, Yeh H-T (1997) The seventh copy of IS1 in Escherichia coli W3110 belongs to the IS1A(IS1E) type which is the only IS1 type that transposes from chromosome to plasmids. Proc Natl Sci Counc Repub China B 21:100–105Google Scholar
  9. Chew LCK, Tacon WCA, Cole JA (1986) Increased stability of maintenance of pAT153 in Escherichia coli HB101 due to transposition of IS1 from the chromosome into the tetracycline resistance region of pAT153. FEMS Microbiol Lett 36:275–280CrossRefGoogle Scholar
  10. Deonier RC (1987) Locations of native insertion sequence elements. In: Neidhardt F (ed) Escherichia coli and Salmonella typhimurium: cellular and molecular biology. American Society for Microbiology, Washington, DC, pp 982–989Google Scholar
  11. Donnelly J, Berry K, Ulmer JB (2003) Technical and regulatory hurdles for DNA vaccines. Int J Parasitol 33:457–467CrossRefGoogle Scholar
  12. Dower WJ, Miller JF, Ragsdale CW (1988) High efficiency transformation of E. coli by high voltage electroporation. Nucleic Acids Res 16:6127–6145Google Scholar
  13. Dunham SP (2002) The application of nucleic acid vaccines in veterinary medicine. Res Vet Sci 73:9–16CrossRefGoogle Scholar
  14. Galas D, Calos MP, Miller JH (1980) Sequence analysis of Tn9 insertions in the lacZ gene. J Mol Biol 144:19–41CrossRefGoogle Scholar
  15. Gurunathan S, Klinman DM, Seder RA (2000) DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 18:927–974CrossRefGoogle Scholar
  16. Hall BG (1998) Activation of the bgl operon by adaptive mutation. Mol Biol Evol 15:1–5Google Scholar
  17. Hensley S (2005) Vaccines that keep salmon safe to eat may help humans. In: Wall St. Journal (Eastern edition). New York, p B.1Google Scholar
  18. Itoh M, Suzuki T, Kimata Y, Kawai K, Horitsu H, Takamizawa K (1994) Cadmium resistance acquirement by IS1 transposition into Escherichia coli C600. J Ferment Bioeng 78:466–468CrossRefGoogle Scholar
  19. Kitamura K, Torii Y-i, Matsuoka C, Yamamoto K (1995) DNA sequence changes in mutations in the tonB gene on the chromosome of Escherichia coli K12: insertion elements dominate the spontaneous spectra. Jpn J Genet 70:35–46CrossRefGoogle Scholar
  20. Klotsky R-A, Schwartz I (1987) Measurement of cat expression from growth-rate-regulated promoters employing b-lactamase activity as an indicator of plasmid copy number. Gene 55:141–146CrossRefGoogle Scholar
  21. Kobayashi K, Tsukagoshi N, Aono R (2001) Suppression of hypersensitivity of Escherichia coli acrB mutant to organic solvents by integrational activation of the acrEF operon with the IS1 or IS2 element. J Bacteriol 183:2646–2653CrossRefGoogle Scholar
  22. Leitner WW, Thalhamer J (2003) DNA vaccines for non-infectious diseases: new treatments for tumour and allergy. Expert Opin Biol Ther 3:627–638CrossRefGoogle Scholar
  23. Lekutis C, Shiver JW, Liu MA, Letvin NL (1997) HIV-1 env DNA vaccine administered to Rhesus monkeys elicits MHC Class II-restricted CD4+ T helper cells that secrete IFN-g and TNF-a. J Immunol 158:4471–4477Google Scholar
  24. Liang X, Fu T-M, Xie H, Emini EA, Shiver JW (2002) Development of HIV-1 Nef vaccine components: immunogenicity study of Nef mutants lacking myristoylation and dileucine motif in mice. Vaccine 20:3413–3421CrossRefGoogle Scholar
  25. Lin-Chao S, Bremer H (1986) Effect of the bacterial growth rate on replication control of plasmid pBR322 in Escherichia coli. Mol Gen Genet 203:143–149CrossRefGoogle Scholar
  26. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the \(2^{{ - \Delta \Delta C}} _{T}\) method. Methods 25:402–408CrossRefGoogle Scholar
  27. Lowrie DB (1999) DNA vaccines against tuberculosis. Curr Opin Mol Ther 1:30–33Google Scholar
  28. Montgomery DL, Shiver JW, Leander KR, Perry HC, Friedman A, Martinez D, Ulmer JB, Donnelly JJ, Liu MA (1993) Heterologous and homologous protection against Influenza A by DNA vaccination: optimization of DNA vectors. DNA Cell Biol 12:777–783CrossRefGoogle Scholar
  29. Mwau M, McMichael AJ (2003) A review of vaccines for HIV prevention. J Gene Med 5:3–10CrossRefGoogle Scholar
  30. Naas T, Blot M, Fitch WM, Arber W (1994) Insertion sequence-related genetic variation in resting Escherichia coli K-12. Genetics 136:721–730Google Scholar
  31. Naas T, Blot M, Fitch WM, Arber W (1995) Dynamics of IS-related genetic rearrangements in resting Escherichia coli K-12. Mol Biol Evol 12:198–207Google Scholar
  32. Nakahama K, Itoh Y, Fujisawa Y, Kikuchi M (1986) Increased expression of hepatitis B virus surface antigen gene in Escherichia coli by IS1 insertion. Appl Microbiol Biotechnol 25:262–266CrossRefGoogle Scholar
  33. Nakamura K, Inouye M (1981) Inactivation of the Serratia marcescens gene for the lipoprotein in Escherichia coli by insertion sequences, IS1 and IS5; sequence analysis of junction points. Mol Gen Genet 183:107–114CrossRefGoogle Scholar
  34. Namdev PK, Irwin N, Thompson BG, Gray MR (1993) Effect of oxygen fluctuations on recombinant Escherichia coli fermentation. Biotechnol Bioeng 41:666–670CrossRefGoogle Scholar
  35. Ohtsubo E, Sekine Y (1996) Bacterial insertion sequences. In: Saedler H, Gierl A (eds) Transposable elements. Springer, Berlin Heidelberg New York, pp 1–26Google Scholar
  36. Okonkowski J, Kizer-Bentley L, Listner K, Robinson D, Chartrain M (2005) Development of a robust, versatile, and scalable inoculum train for the production of a DNA vaccine. Biotechnol Prog 21:1038–1047CrossRefGoogle Scholar
  37. Powell K (2004) DNA vaccines—back in the saddle again? Nat Biotechnol 22:799–801CrossRefGoogle Scholar
  38. Prather KJ, Sagar S, Murphy J, Chartrain M (2003) Industrial scale production of plasmid DNA for vaccine and gene therapy: plasmid design, production, and purification. Enzyme Microb Technol 33:865–883CrossRefGoogle Scholar
  39. Reinikainen P, Korpela K, Nissinen V, Olkku J, Soderlund H, Markkanen P (1989) Escherichia coli plasmid production in fermenter. Biotechnol Bioeng 33:386–393CrossRefGoogle Scholar
  40. Reinikainen P, Virkajärvi I (1989) Escherichia coli growth and plasmid copy numbers in continuous cultivations. Biotechnol Lett 11:222–230CrossRefGoogle Scholar
  41. Rodriguez H (1992) An Escherichia coli plasmid-based, mutational system in which supF mutants are selectable: insertion elements dominate the spontaneous spectra. Mutat Res 270:219–231Google Scholar
  42. Schirrmacher V (2005) T cell-mediated immunotherapy of metastases: state of the art in 2005. Expert Opin Biol Ther 5:1051–1068CrossRefGoogle Scholar
  43. Schmidt T, Friehs K, Flaschel E, Schleef M (2003) Method for the isolation of ccc plasmid DNA. US Patent 6,664,078. Qiagen GmbHGoogle Scholar
  44. Seo J-H, Bailey JE (1985) Effects of recombinant plasmid content on growth properties and cloned gene product formation in Escherichia coli. Biotechnol Bioeng 27:1668–1674CrossRefGoogle Scholar
  45. Seo J-H, Bailey JE (1986) Continuous cultivation of recombinant Escherichia coli—existence of an optimum dilution rate for maximum plasmid and gene-product concentration. Biotechnol Bioeng 28:1590–1594CrossRefGoogle Scholar
  46. Toba-Minowa M (1992) Characterization of the spontaneous elimination of streptomycin sensitivity (SmS) on high-copy-number plasmids: SmS-enforcement cloning vectors with a synthetic rpsL gene. Gene 121:25–33CrossRefGoogle Scholar
  47. Tuteja R (2002) DNA vaccine against malaria: a long way to go. Crit Rev Biochem Mol Biol 37:29–54CrossRefGoogle Scholar
  48. Ulmer JB (2002) Influenza DNA vaccines. Vaccine 20:S74–S76CrossRefGoogle Scholar
  49. Vilalta A, Whitlow V, Martin T (2002) Real-time PCR determination of Escherichia coli genomic DNA contamination in plasmid preparations. Anal Biochem 301:151–153CrossRefGoogle Scholar
  50. Zerbib D, Gamas P, Chandler M, Prentki P, Bass S, Galas D (1985) Specificity of insertion of IS1. J Mol Biol 185:517–524CrossRefGoogle Scholar
  51. Zhang J, Greasham R (1999) Chemically defined media for commercial fermentations. Appl Microbiol Biotechnol 51:407–421CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Kristala L. Jones Prather
    • 1
    • 2
  • M. Celina Edmonds
    • 1
  • Jerrell W. Herod
    • 3
  1. 1.Biocatalysis and Fermentation Development, Bioprocess R&DMerck Research LaboratoriesRahwayUSA
  2. 2.Department of Chemical EngineeringMassachusetts Institute of TechnologyCambridgeUSA
  3. 3.John Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations